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Introduction
Mortality is related with cardiovascular dis-
ease in approximately 50 percent of patients with
chronic kidney disease (CKD)(1,2). Many traditional
and non-traditional risk factors cause cardiovascu-
lar events in these patients. Traditional risk factors
such as hyperlipidemia, hypertension, and diabetes
alone are insufficient to explain the high cardiovas-
cular morbidity and mortality in patients with CKD.
Increasing evidences bring the role of non-tradi-
tional risk factors to the fore such as oxidative
stress and inflammation(3).
The perception in which adipose tissue is
known as storage location of fatty acids has changed
in recent years. It has been figured out that gradually
increasing evidences show that adipose tissue mass
is directly related with both systemic inflammation
and cardiovascular risk increase with number of
cytokines such as adiponectin, leptin, pentraxin-3
playing a central role in glucose and lipid metabo-
lism(4, 5). Adiponectin is a very sensitive indicator of
prediction for cardiovascular events(6). It has been
shown that serum leptin, and pentraxin-3 levels are
closely related with stroke, chronic heart failure,
acute myocardial infarction, coronary heart disease(7,
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ABSTRACT
Introduction: Increase in visceral adipose tissue (VAT) is associated with cardiovascular risk. However, the relationship
between atherosclerosis and VAT has not yet been adequately studied in chronic kidney disease (CKD). The aim of this study was to
assess the relationship among VAT, adipokines, and atherosclerosis in patients with CKD. 
Materials and methods: 45 healthy control, 53 predialysis patients, and 52 hemodialysis patients have been enrolled in the
study. Intima media thickness (IMT) of the carotid artery, and VAT measurements were evaluated via ultrasonography. 
Results: IMT (p:0.002), VAT (p:0.021), adiponectin (p<0.001) and pentraxin-3 (p:0.003) were higher in predialysis patients
than healthy controls. The values of IMT (p<0.001), VAT (p:0.0014), adiponectin (p:0.005), pentraxin-3 (p: <0.001), C reactive pro-
tein (CRP) (p:0.009), triglyceride (p: <0.001) and parathyroid hormone (PTH) (p<0.001), were higher in hemodialysis patients than
healthy controls. VAT was positively correlated with CRP(r: 0, 23 p: 0.005), IMT (r: 0.347 p<0.001), body mass index (BMI) (r: 0.33
p<0.001), and negatively correlated with creatinine clearance (R: -0.245 p: 0.003). VAT is independently related with adiponectin
(β:-0.213 p: 0.008), BMI (β: 0.369, P<0.001), and CRP (β:0.164, P:0.032) in multiple regression analysis. IMT was positively corre-
lated with VAT (r: 0.347 p<0.001), CRP (r: 0.186 p: 0.022), age (r: 0.333 p<0.001), BMI (r: 0.444 p<0.001) in all participants.
Conclusion: These findings show that VAT is a strong risk factor for atherosclerosis in patients with CKD. However IMT was
not correlated with adiponectin, pentraxin-3, and leptin in patients with CKD.  Also sonographic measurement of VAT could be use-
ful to stratify the risk of cardiovascular disease in patients with CKD. 
Keywords: visceral adipose tissue, intima media thickness, adiponectin, leptin, Pentraxin-3, Chronic Kidney Disease.
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8). It has been demonstrated in previous study that
visceral adipose tissue (VAT) has increased in
patients with CKD, and associated with atherosclero-
sis(9). However, the relationship between VAT and
atherosclerosis is still unknown exactly. The aim of
this study was to assess the relationship among VAT,
cytokines originating from visceral fat such as
adiponectin, leptin, and Pentraxin-3, and atheroscle-
rosis in patients with CKD.  
Material and methods 
The study protocol was approved by the
Pamukkale University Ethical Committee. A con-
trol group of 45 healthy individuals (Group-1), 53
predialysis patients (Group-2), and 52 hemodialysis
patients (Group-3) have been enrolled in the study.
The study was performed in Pamukkale University
Faculty of Medicine between February, 2011 and
November, 2011. Exclusion criteria included those
under 18, and above 80, who had active infections,
coronary artery disease, history of percutaneous or
surgical revascularization, congenital heart disease,
inflammatory diseases, malignancy, and diabetes
mellitus. The glomerular filitration rate (GFR) of
the patients with chronic renal failure is between
60-15 ml/min. All of the hemodialysis patients had
been receiving hemodialysis 3 times per week with
bicarbonate dialysate solution at least for one year.
Systolic and diastolic blood pressure was measured
in each individual twice, following a 5-minute rest,
with erka brand sphygmomanometer using an
appropriate cuff width. Those with blood pressure ≥
140/90 mmHg and using anti-hypertensive drugs
are accepted as hypertensive patients. Those with
serum total cholesterol ≥ 200 mg/dl and/or triglyc-
erides ≥ 150 mg/dl and using lipid-lowering drugs
are accepted as hyperlipidemic patients.
Laboratory analysis
Blood samples were collected in all subjects in
the study at 8 in the morning after 12 hours of fast-
ing. Blood samples were collected in hemodialysis
patients prior to dialysis treatment. Imaging tech-
nique was carried out within 2 hours after blood
samples had been collected. The adiponectin plas-
ma levels (RD195023100, Human Adiponectin,
Elisa Bio Vendor Laboratory Medicine Inc., Brno,
Czech Republic),  the leptin plasma levels (RD
191001100 Human leptin ELISA kit, Bio Vendor
GmbH, Heidelberg, Germany), and human
Pentraxin-3/TSG-14 plasma levels (Quantikine
ELISA kit, R&D Systems, Minneapolis, Minn,
Catalog Number DPTX30)were measured with
immunoassay. Immulite 2000 analyzer was used for
the measurement of Insulin; Sysmex XT 2000I ana-
lyzer was used for the measurement of complete
blood; Modular P and Roche/Hitachi analyzer was
used for the measurement of others parameters.
Homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated from fasting blood glu-
cose (FBG) and fasting insuline (FI) levels using
the following formula; {FBG (mg/dl) × FI
(mu/ml)}/405 (10). Also GFR was calculated with
The Modification of Diet in Renal Disease method
(MDRD) in all individuals in the study.  MDRD
was calculated as GFR (ml / min / 1.73 m 2) = 186
x (Scr) -1154 x (Age) -0203 x (0.742 if you are a
woman).
Carotid intima media thickness measurement
IMT of the carotid artery as an indicator of
subclinical atherosclerosis was measured. Carotid
artery ultrasounds of all groups were applied by a
single radiologist in Pamukkale University
Department of Radiology, Medical Faculty
Hospital. Toshiba aplio XY high-resolution B-mode
ultrasonography with 7.5 MHz linear probe was
used in the measurements. The measurement in
between two echogenic lines seen between intima
lumen interface and media adventitia interface was
described as IMT measurement(11). Posterior wall
was used in the measurement as performed in the
axial and longitudinal plans in views. Imaging tech-
niques were performed within 2 hours after blood is
collected from patients.  
Visceral adipose tissue measurement
VAT measurements of all groups were applied
by a single radiologist in Pamukkale University
Medical Faculty Hospital, Department of
Radiology. Toshiba aplio XY high-resolution B-
mode ultrasonography with 3.5 MHz convex probe
was used in the measurements. Measurements were
performed via 3.5 MHz convex probe placed 1 cm
beyond umbilicus after an overnight fast while
patients lying supine. By means of taking 3 samples
from the distance in between skin and rectus abdo-
minis, the average value of these samples was
accepted as subcutaneous adipose tissue. By means
of taking 3 samples from the distance in between
inner fascia of rectus abdominis and front fascia of
the abdominal aorta the average value of these sam-
ples was accepted as VAT(12). 
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Statistical analysis
Statistical analyses were carried out using the
Statistical package for Social Sciences for Windows
version 10.0 (SPSS, Chicago, IL, USA) in
Pamukkale University School of Medicine
Department of Biostatistics. Descriptive statistics
for each variable were determined. Results for con-
tinuous variables were demonstrated as mean± stan-
dard deviation. Pearson's correlation coefficient,
Spearman correlation coefficient, Mann Whitney U
test, two of the difference between the means test,
chi-square test, kruskal-wallis ANOVA, one-way
analysis of variance, and Bonferroni correction
Mann-Whitney U test were used for comparing the
studied groups. Statistical significance was defined
as P< 0.05
Results
The study groups consisted of a control group
(n: 45), a predialysis group (n: 53), and a dialysis
group (n: 52). The basal characteristics and labora-
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Control Group Predialysis Group Dialysis Group P
Statistical differences between groups
K-PD K-D D-PD
Gender(M/F) 23/22 28/25 26/26 >0.05 >0.05 >0.05 >0.05
Age (year) 48.66±9.40 53.26±11.37 50.36±11.12 >0.05 0.334 0.736 0.736
Duration of CKD 0 49.64±47.14 93.53±63.09 <0.001 <0.001 <0.001 <0.001
BMI 27.57±3.82 26.02±3.81 25.18±3.06 0.005 <0.001 <0.001 0.389
Triglyceride (mg/dl) 156.63±99.51 169.13±107.45 183.34±106.15 >0.05 0.981 0.577 0.861
LDL (mg/dl) 120.54±31.49 110.22±43.25 104.77±33.96 >0.05 0.782 0.181 0.802
HDL(mg/dl) 44.97±9.2 49.39±17.02 46.20±14.56 >0.05 >0.05 >0.05 >0.05
T. cholesterol (mg/dl) 193.75±34.53 195.99±54.69 187.67±47.55 >0.05 0.995 0.921 0.836
CRP (mg/dl) 0.42±0.29 1.11±1.89 1.71±4.37 0.037 0.081 0.009 0.59
Glucose (mg/dl) 96.08±15.24 100.73±27.80 96.85±17.84 >0.05 0.992 0.998 0.999
HOMA-İR 2.24±1.55 4.23±5.042 3.85±3.15 >0.05 0.698 0.116 0.775
Sist. B.P. (mmHg) 119.77±12.87 125.94±17.70 121.25±12.04 >0.05 0.08 0.959 0.193
Diast. B.P. (mmHg) 77.66±9.02 79.90±11.201 75.57±7.77 >0.05 0.66 0.702 0.133
Calcium (mg/dl) 9.16±0.36 8.89±0.66 8.92±0.71 0.066 0.076 0.141 0.955
Phosphor (mg/dl) 3.41±0.60 4.1±0.75 4.8±1.02 <0.001 <0.001 <0.001 <0.001
Albumin (mg/dl) 4.56±0.23 4.10±0.57 4.1±0.50 <0.001 <0.001 <0.001 >0,05
Duration of smoking
(year) 5.84±12.75 10.62±14.52 8.26±12.18 >0.05 0.041 0.227 0.227
Creatinine Clearance
(ml/mn) 116.20±29.07 32.22±12.52 8.76± 3.87 0.0001 <0.001 <0.001 <0.001
PTH (pg/ml) 59.36±20.29 191.28±161.14 501.00±594.31 0.0001 0.474 <0.001 0.001
Ferritin (ng/dl) 58.71±47,35 138.52±126.37 519.35±450.60 0.0001 0.364 <0.001 <0.001
Hemoglobin (g/dl) 13.42±1.68 11.62±1.58 11.41±1.61 0.0001 <0.001 <0.001 0.965
İMT (MM) 0.66±0.11 0.76±0.14 0.84±0.12 0.0001 0.002 <0.001 0.048
Adiponectin (µg/mL) 6.17± 3.21 11.52± 8.22 10.46± 5.73 0.0001 <0.001 0.005 0.542
Leptin (ng/mL) 24.48 ±  22.22 22.78 ± 18.98 22.53 ±  22.51 >0.05 0.999 0.97 0.993
Pentraxin-3  (ng/mL) 0.36 ±  0.25 0.79 ± 0.65 0.96±  0.73 0.0001 0.003 <0.001 0.849
SAT 20.33± 6.02 19.86± 8.39 20.10 ± 7.045 >0,05 0.965 0,999 0,998
VAT 51.25± 51.25 63.06± 22.72 63.78± 20.41 0.004 0.021 0.014 0.998
Table 1: The basal characteristics and laboratory parameters of the control group, predialysis group, and dialysis group.
Abbreviations: Duration of CKD: Duration of chronic kidney disease, BMI: Body mass Index, LDL: Low density lipoprotein, HDL:
High density lipoprotein T. cholesterol: Total cholesterol , CRP: C reactive protein,  HOMA-İR: The threshold value for insulin resi-
stance, Sist. B.P.: Systolic blood pressure Diast. B.P.: Diastolic blood pressure PTH: Parathyroid hormone, Cr. Cl: Creatinine clea-
rance, İMT: Carotid Intima-Media Thickness, SAT: subcutaneous adipose tissue, VAT: visceral adipose tissue
tory parameters of the control group, predialysis
group, and dialysis group are shown in table 1.
The values of age, sex, triglycerides, low den-
sity lipoprotein (LDL), High density lipoprotein
(HDL), total cholesterol, HOMA-IR, systolic blood
pressure, diastolic blood pressure, duration of
smoking, leptin, and subcutaneous adipose tissue
were not detected to be significantly different
among three groups (table 2).
The values of IMT (p: 0.002), VAT (p: 0.021),
adiponectin (p<0.001), pentraxin-3 (p: 0.003), crea-
tinine clearance (p<0.001), hemoglobin (p<0.001),
albumin (p p<0.001), phosphorus (p<0.001), BMI
(p<0.001), and duration of CKD were detected to
be significantly higher in predialysis patients than
in healthy control group. The values of IMT
(p<0.001), VAT (p:0.0014), adiponectin (p: 0,005),
pentraxin-3 (p<0.001), CRP (p: 0,009), creatinine
clearance (p<0.001), PTH (p<0.001), duration of
CKD (p<0.001), albumin (p<0.001), phosphorus
(p<0.001), Ferritin (p<0.001), were detected to be
significantly higher in hemodialysis patients than
group of healthy control. The values of duration of
CKD (p<0.001), phosphorus (p<0.001), and PTH
(p: 0.001) were detected to be significantly higher
in hemodialysis patients than group of predialysis
patients. The values of BMI (p<0.001), and hemo-
globin (p<0.001), were detected to be significantly
lower in predialysis patients than group of healthy
control. The values of BMI (p<0.001), and hemo-
globin (p<0.001), were detected to be significantly
lower in dialysis groups than in predialysis patients
(table 1). No significant difference was detected in
the frequency of statin and antihypertensive drug
use among three groups (table 2).
VAT was significantly positively correlated
with CRP (r: 0.23p: 0,005), IMT (r: 0,347 p<0.001),
BMI (r: 0,33 p<0.001), and negatively correlated
with creatinine clearance (r: -0,245 p: 0,003) in all
participants in the correlation analysis. It was detect-
ed that IMT was significantly correlated with VAT
(r: 0,347 p<0.001), CRP (r: 0.186 p: 0.022), age (r:
0.333 p<0.001), BMI (r: 0.444 p<0.001), and in a
negative correlation with creatinine clearance (r: -
0,451 p<0.001), in all participants in the correlation
analysis (table 3). IMT was not correlated with
adiponectin, pentraxin-3, and leptin levels in
patients with CKD. It was shown that adiponectin
was in a negative correlation with VAT in all
patients with CKD (r: -0.233 P: 0.017) (table 4). 
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Control Predialysis Dialysis P
Antihypertensive
medication use. 6/45(%13) 30/53(%65) 10/52(%28) >0,05
Statin medication use 3/45(%14) 9/53(%16) 10/52(%19) >0,05
Table 2: Antihypertensive and statin medication use in
the study groups. 
İMT VAT
R P R P
Age (year) 0.333* <0.001 0.15 0.067
BMI(kg/cm2) 0.444* <0.001 0.33* <0.001
Cr. Cl. (ml/mn) -0.451* <0.001 -0.245* 0.003
T. cholesterol (mg/dl) -0.0129 0,115 0.052 0.53
Triglyceride (mg/dl) -0.008 0,924 0.148 0.072
LDL (mg/dl) -0.147 0,073 0.049 0.549
CRP (mg/dl) 0.186* 0,022 0.23* 0.005
Table 3: Correlation analysis of visceral adipose tissue
and carotid intima media in all study groups. 
Adiponectin Pentraxin-3 Leptin
R P R P R P
Age (year) -0,024 0,81 -0,034 0,73 0,047 0,638
BMI(kg/cm2) -0,16 0,103 0,149 0,128 0,035 0,724
Cr. Cl. (ml/mn) 0,165 0,092 0 0,997 0,112 0,257
T. cholesterol (mg/dl) 0,021 0,832 0,033 0,736 0,151 0,124
Triglyceride (mg/dl) -0,037 0,704 0,089 0,368 0,161 0,102
LDL (mg/dl) -0,036 0,718 0,02 0,839 0,074 0,456
İMT (mm) -0,068 0,493 -0,028 0,777 -0,156 0,112
VAT (mm) -0,233* 0,017* 0,14 0,153 -0,088 0,372
SAT  (mm) -0,084 0,397 1 -0,13 0,185
Table 4: Correlation analysis of adiponectin, Pentraxin-
3, and leptin in all patients of chronic kidney disease.
Abbreviations: BMI: Body mass Index, LDL:low density lipo-
protein, HDL:High density lipoprotein T. cholesterol: Total
cholesterol, Cr. Cl.: Creatinine clearance, İMT: Carotid
Intima-Media Thickness.VAT: visceral adipose tissue, SAT:
subcutaneous adipose tissue, *: p˂005
B Std. Error Beta p 95% CI (Lower - Upper)
Bmi 0,704 0,151 0,369 0,0001* 0,405 - 1,002
Adipo -0,673 0,249 -0,213 0,008* -1,164 - 0,182
crp 1,201 0,555 0,164 0,032* 0,104 - 2,297
Table 5: Multiple regression analysis of markers affec-
ting visceral adipose tissue in all groups.
Model p: 0.00001; R2:0.185; Adj. R2: 0.168; 95% CI :95% con-
fidence interval; BMI: Body mass Index; CRP: C-reactive pro-
tein
Upon the assessment of variables effecting
VAT such as BMI, HOMA-IR, triglycerides, CRP,
pentraxin-3, adiponectin, leptin, age, creatinine
clearance in all the patients in our study via multi-
ple regression analysis, it was detected that VAT is
independently in a negative correlation with
adiponectin (β: -0.213 p: 0.008), and in a positive
correlation with BMI (β: 0.369, P: 0.004) and CR P
(β:0.164, P:0.032) in multiple regression analysis
(Table 5). 
Discussion
In our study, we showed that VAT, IMT,
adiponectin, and pentraxin-3 were higher in patients
with CKD and hemodialysis patients, and also that
VAT is significantly correlated with IMT and CRP
and is in a negative correlation with creatinine
clearance, and adiponectin.  
In accordance with our study, Odamaki et. al.
showed that VAT was higher in hemodialysis
patients(13). It was demonstrated in the PREVEND
study that creatinin levels were negatively correlat-
ed with central obesity in 7676 patients without dia-
betes mellitus(14). In a change reaction, increase in
VAT leads to an increase in the production of
angiotensin in adipose tissue(15). Respectively, this
increase in angiotensin causes increase in blood
pressure(16), endothelial dysfunction, and finally a
decrease in GFR(17). Also, increased VAT contributes
renal damage and a reduction in GFR as cause intra
renal pressure via to physically compress kid-
ney(18).We showed in our study that VAT was related
with IMT in hemodialysis and patients with chronic
renal failure. It has been shown in the recent studies
that VAT is correlated with IMT and coronary artery
calcification in patients with chronic renal failure(19,
20, 21). These findings have shown that increase in
VAT induces atherosclerosis. It has been shown that
the increase of VAT is related with strong cardio-
vascular risk factors such as inflammation(22) oxida-
tive stress(23, 24), and increased small dense LDL par-
ticles(25, 26). In accordance with literature, VAT had a
correlation with CRP in our study, as well. In the
recent studies, it has been shown that a great num-
ber of inflammatory cytokines which can increase
atherosclerosis risk are secreted from VAT(27, 28).
In our study, adiponectin and pentraxin-3 were
detected to be higher in kidney failure patients in
comparison with healthy males and females. We did
not detect a significant difference in the leptin lev-
els of kidney failure patients and control group
individuals. In accordance with our study, it was
detected that adiponectin level was higher in
patients with chronic renal failure(29, 30, 31). Still in
accordance with our study, it was shown that
adiponectin was in a negative correlation with
VAT(32, 33).
In our study, we did not detect a statistically
significant correlation between adiponectin and
IMT. In accordance with our study, Nakanishi et al,
and Rubio et al did not detect any correlation
between adiponectin and IMT in patients with dia-
betes mellitus(34), and hypertension(34, 35). The reason
why we did not detect a significant correlation
between adiponectin and IMT may be due to the
changes in adiponectin metabolism, posttranslation-
al modifications, or abnormal accumulation of
metabolites in CKD(36).
In accordance with our study, Maloponte et al.
showed that PTX3 plasma level is higher in uremic
patients(37). Boheme et al. detected that PTX-3 plas-
ma level increased in hemodialysis patients(38). Also,
it was shown that PTX-3 level was higher in
patients with chronic renal failure(39). In accordance
with our study, any statistical difference in the lep-
tin levels of healthy control individuals and chronic
renal failure patients was not detected in some stud-
ies such as Heimburger et al(40) and Stevinkel et al(41).
In our study, it was detected that upon the
analysis of parameters effecting IMT in CKD
patients, there happened to be a relationship among
age, CRP and VAT. Age is one of the independent
risk factors in coronary artery disease. In accor-
dance with our study, it was demonstrated in the lit-
erature that IMT was positively correlated with
age(42, 43). As is in previous studies in literature(44, 45), it
was also shown in our study that CRP was in a pos-
itive correlation with IMT and that CRP was posi-
tively correlated with IMT. 
Usually, VAT was measurement via tomogra-
phy in the literature. Ultrasonography is harmless,
relatively inexpensive, available, and there is no
ionizing radiation.Our findings show that sono-
graphic measurement of VAT could be useful to
stratify the risk of cardiovascular disease in patients
with CKD.  
Our findings showed that increase in VAT is in
a relation with the decrease in creatinine clearance,
inflammation, and the increase of atherosclerosis
risk. This positive relation points out to the fact that
inflammatory cytokines caused by VAT take a role
in accelerated atherosclerosis. Finding out the rela-
tion among the accelerated atherosclerosis, VAT,
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and inflammation in CKD can shed light on the
new approaches in the treatment to prevent high
cardiovascular mortality, the most important prob-
lem in these patients. 
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